Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Avalon GloboCare ( (ALBT) ) is now available.
On March 30, 2026, Avalon GloboCare shareholders approved a series of financing-related measures, including the issuance of common shares upon conversion of prior convertible notes, a December 2025 bridge note, and Series C preferred stock. Investors also backed an exchange with Chairman Wenzhao Lu of Series D preferred stock into over 2 million common shares and the issuance of restricted stock to a consultant for advisory services, confirming a broad mandate to restructure the firm’s capital base.
Stockholders furthermore authorized a reverse stock split at a ratio between 1-for-2 and 1-for-25 to be implemented at the board’s discretion before March 30, 2028, without reducing authorized share count. The meeting also approved the potential adjournment of the session to solicit additional proxies if needed, strengthening the board’s flexibility to manage Nasdaq listing compliance and future equity transactions, with votes showing solid support across the proposals.
More about Avalon GloboCare
Avalon GloboCare Corp. operates in the healthcare and biotechnology sector, focusing on advanced cell-based technologies, diagnostics, and related medical services. The company’s activities center on developing and commercializing innovative biomedical solutions, positioning it within specialized life sciences markets that often rely on access to capital and adherence to stock exchange listing standards.
Average Trading Volume: 6,697,484
Technical Sentiment Signal: Sell
Current Market Cap: $3.54M
For detailed information about ALBT stock, go to TipRanks’ Stock Analysis page.